ReproductiveFDA Approved

PT-141

Also known as Bremelanotide · Vyleesi

Melanocortin-4 receptor agonist FDA-approved for HSDD in premenopausal women.

Overview

Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin agonist with preferential activity at MC4R. Approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women.

Mechanism

MC4R-preferential melanocortin agonism in CNS sexual-response circuits.

Research areas

HSDD
CNS sexual response
Ischemia models

Related peptides

Melanotan II

Synthetic cyclic analog of α-MSH; non-selective melanocortin receptor agonist.

View

Kisspeptin-10

C-terminal decapeptide fragment of kisspeptin; potent GnRH secretagogue.

View